相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action
Yingyan Xue et al.
EXPERT OPINION ON DRUG DELIVERY (2021)
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy
Satyen H. Gohil et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade
Amber G. Bozward et al.
FRONTIERS IN IMMUNOLOGY (2021)
The Crosstalk Between Cancer Cells and Neutrophils Enhances Hepatocellular Carcinoma Metastasis via Neutrophil Extracellular Traps-Associated Cathepsin G Component: A Potential Therapeutic Target
Xiangqian Guan et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)
CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data
Muhammad Yasir Anwar et al.
JOURNAL OF GASTROINTESTINAL CANCER (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Heterogeneity of Treg/Th17 According to Cancer Progression and Modification in Biliary Tract Cancers via Self-Producing Cytokines
Mitsuru Kinoshita et al.
DIGESTIVE DISEASES AND SCIENCES (2020)
Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma
Sylvie Job et al.
HEPATOLOGY (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Advances in molecular classification and precision oncology in hepatocellular carcinoma
Sandra Rebouissou et al.
JOURNAL OF HEPATOLOGY (2020)
Preoperative Neutrophil-to-lymphocyte Ratio Predicts Tumor-infiltrating CD8+ T Cells in Biliary Tract Cancer
Ryota Tanaka et al.
ANTICANCER RESEARCH (2020)
Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Donghua Shi et al.
CLINICAL CANCER RESEARCH (2020)
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
Sarina A. Piha-Paul et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
Robin Kate Kelley et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01).
Vaibhav Sahai et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).
Do-Youn Oh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
Changhoon Yoo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune-based therapies for hepatocellular carcinoma
David J. Pinato et al.
ONCOGENE (2020)
Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort
Toshihiko Doi et al.
ONCOLOGIST (2020)
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial
Oliver Klein et al.
JAMA ONCOLOGY (2020)
Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma
Jianzhen Lin et al.
HEPATOBILIARY SURGERY AND NUTRITION (2020)
Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response
Jingjing Li et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
Immunosuppressive tumor microenvironment in occupational cholangiocarcinoma: Supportive evidence for the efficacy of immune checkpoint inhibitor therapy
Yasunori Sato et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2020)
Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
Shu-Kui Qin et al.
CANCER SCIENCE (2020)
Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Lipika Goyal et al.
CLINICAL CANCER RESEARCH (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
Lingyu Tian et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2020)
The hepatic microenvironment and regulatory T cells
Daniel Osei-Bordom et al.
CELLULAR IMMUNOLOGY (2020)
The potential application of PD-1 blockade therapy for early-stage biliary tract cancer
Kumiko Umemoto et al.
INTERNATIONAL IMMUNOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study
Mark Yarchoan et al.
CANCER RESEARCH (2020)
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine
Lorenza Rimassa et al.
JOURNAL OF AUTOIMMUNITY (2019)
Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
Tatsuya Ioka et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications
Fei Yu et al.
BIOSCIENCE TRENDS (2019)
HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
Chu-Yu Jing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2019)
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastislav Bahleda et al.
CLINICAL CANCER RESEARCH (2019)
Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules
Guoying Zhou et al.
JOURNAL OF HEPATOLOGY (2019)
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma
Marina Ruiz de Galarreta et al.
CANCER DISCOVERY (2019)
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Panagiotis A. Konstantinopoulos et al.
JAMA ONCOLOGY (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma
Jiaqiang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations
Raja R. Narayan et al.
CANCER (2019)
Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy
Renumathy Dhanasekaran et al.
GASTROENTEROLOGY (2019)
Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer
Changqing Xie et al.
HEPATOLOGY (2019)
Mucosal-associated invariant T cells and disease
Amine Toubal et al.
NATURE REVIEWS IMMUNOLOGY (2019)
New emerging targets in cancer immunotherapy: the role of LAG3
Hannah Christina Puhr et al.
ESMO OPEN (2019)
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells
Chi Ma et al.
SCIENCE (2018)
The immune contexture of hepatocellular carcinoma predicts clinical outcome
Friedrich Foerster et al.
SCIENTIFIC REPORTS (2018)
Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets
Noor-ul-Ain Tariq et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Benjamin D. Hopkins et al.
NATURE (2018)
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Fatima Karzai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Emerging role of precision medicine in biliary tract cancers
James M. Bogenberger et al.
NPJ PRECISION ONCOLOGY (2018)
Precision medicine in cholangiocarcinoma
Antonio Pellino et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Characterisation of the immune-related transcriptome in resected biliary tract cancers
Michele Ghidini et al.
EUROPEAN JOURNAL OF CANCER (2017)
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia et al.
GASTROENTEROLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Marta Luksza et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Identification of essential genes for cancer immunotherapy
Shashank J. Patel et al.
NATURE (2017)
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Apinya Jusakul et al.
CANCER DISCOVERY (2017)
Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis
Ying Wang et al.
JOURNAL OF CANCER (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
Faiz Gani et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Andrew Gabrielson et al.
CANCER IMMUNOLOGY RESEARCH (2016)
BTLA identifies dysfunctional PD-1-expressing CD4(+) T cells in human hepatocellular carcinoma
Qiyi Zhao et al.
ONCOIMMUNOLOGY (2016)
Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review
Viraj Lavingia et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Xiangjiao Meng et al.
CANCER TREATMENT REVIEWS (2015)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway
Maolan Li et al.
NATURE GENETICS (2014)
Mutational landscape of intrahepatic cholangiocarcinoma
Shanshan Zou et al.
NATURE COMMUNICATIONS (2014)
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Yuchen Jiao et al.
NATURE GENETICS (2013)
Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma
Koichi Shimizu et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2012)
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Tanios Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Increased intratumoral IL-17-producing cells survival in hepatocellular carcinoma correlate with poor patients
Jing-Ping Zhang et al.
JOURNAL OF HEPATOLOGY (2009)
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment
Anuradha Budhu et al.
CANCER CELL (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
分享论文
